Annexon Biosciences to Participate in Upcoming May Investor Conferences

Rhea-AI Summary

Annexon, Inc. (Nasdaq: ANNX) announced that CEO Douglas Love will participate in upcoming investor conferences: the BofA Securities 2022 Healthcare Conference on May 12, 2022, in Las Vegas, and the H.C. Wainwright Global Investment Conference on May 25, 2022, in Miami. The company specializes in developing complement-targeting medicines for autoimmune, neurodegenerative, and ophthalmic disorders. Webcasts of the events will be available on the company's website for 30 days post-conference. Annexon is advancing several clinical-stage candidates, including ANX005, ANX007, and ANX009.

BRISBANE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following May investor conferences:

• BofA Securities 2022 Healthcare Conference on Thursday, May 12, 2022, at 12:00 p.m. PT in Las Vegas; and,
• H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022, at 10:00 a.m. ET in Miami, Fl.

Live webcasts of the presentations can be accessed under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com. Replays of the webcasts will be archived on the Annexon website for 30 days following the presentations.

About Annexon

Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company pioneering a new class of complement medicines designed to stop the classical complement pathway at its start, C1q, to bring therapies to patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders. The company’s proprietary complement-targeting platform utilizes well-researched classical complement-mediated autoimmune and neurodegenerative processes triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a broad portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway, which may provide more complete protection against complement-mediated disorders of the body, brain and eye. The company’s pipeline includes three clinical-stage drug candidates, ANX005 (intravenous administration), ANX007 (intravitreal administration), and ANX009 (subcutaneous administration), as well as a robust early-stage pipeline of preclinical and discovery stage programs. Annexon is deploying a disciplined, biomarker-driven strategy designed to improve the probability of technical success of its portfolio. For more information, visit www.annexonbio.com.

Contact:

Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com

FAQ

When will Annexon CEO Douglas Love speak at the BofA Securities 2022 Healthcare Conference?

Douglas Love will speak at the BofA Securities 2022 Healthcare Conference on May 12, 2022, at 12:00 p.m. PT in Las Vegas.

What are the details of the H.C. Wainwright Global Investment Conference for Annexon?

Douglas Love will participate in the H.C. Wainwright Global Investment Conference on May 25, 2022, at 10:00 a.m. ET in Miami, FL.

How can I access the webcasts of Annexon's investor presentations?

Webcasts of Annexon's presentations can be accessed on their website under the ‘Events & Presentations’ section and will be archived for 30 days after the events.

What is Annexon known for in the biopharmaceutical industry?

Annexon is known for pioneering a new class of complement medicines targeting autoimmune, neurodegenerative, and ophthalmic disorders.

What clinical-stage candidates is Annexon currently developing?

Annexon is developing several clinical-stage candidates, including ANX005, ANX007, and ANX009, targeting the classical complement pathway.